🇺🇸 FDA
Patent

US 10912797

Tumor infiltrating lymphocytes and methods of therapy

granted A61KA61K2239/31A61K2239/38

Quick answer

US patent 10912797 (Tumor infiltrating lymphocytes and methods of therapy) held by THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH
Grant date
Tue Feb 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
33
CPC classes
A61K, A61K2239/31, A61K2239/38, A61K2239/52, A61K2239/57